Table 2. Univariate analysis of patient characteristics for overall survival (n = 408).
| Parameter | n | Overall survival (months) |
HR (95% CI) | P | |
| Median | 95% CI | ||||
| Sex | 0.826 | ||||
| Female | 66 | 23.3 | 16.4-30.2 | ||
| Male | 342 | 25.1 | 22.1-28.0 | 1.0 (0.7-1.5) | |
| Age (years) | 0.459 | ||||
| < 47 | 197 | 26.0 | 20.8-31.1 | ||
| ≥ 47 | 211 | 23.3 | 19.1-27.6 | 1.1 (0.9-1.4) | |
| Pathologic type | 0.900 | ||||
| WHO I/II | 17 | 31.8 | 14.7-48.8 | ||
| WHO III | 391 | 24.7 | 22.0-27.4 | 1.0 (0.5-1.9) | |
| Period of diagnosis | 0.011 | ||||
| 2000 to 2005 | 201 | 23.3 | 18.8-27.9 | ||
| 2006 to 2009 | 207 | 25.1 | 19.8-30.3 | 0.7 (0.5-0.9) | |
| KPS | 0.025 | ||||
| < 90 | 104 | 18.9 | 12.8-25.0 | ||
| ≥ 90 | 304 | 26.9 | 23.4-30.4 | 0.7 (0.5-0.9) | |
| T classification | 0.454 | ||||
| T1-2 | 157 | 25.3 | 21.9-28.8 | ||
| T3-4 | 251 | 24.6 | 20.3-28.5 | 0.9 (0.7-1.2) | |
| N classification | 0.003 | ||||
| N0-1 | 144 | 30.5 | 23.2-37.7 | ||
| N2-3 | 264 | 21.9 | 19.0-24.9 | 1.5 (1.1-2.0) | |
| Bone metastasis | 0.725 | ||||
| Absent | 145 | 24.6 | 21.1-28.0 | ||
| Present | 263 | 27.0 | 22.7-31.3 | 1.0 (0.7-1.2) | |
| Liver metastasis | 0.008 | ||||
| Absent | 261 | 28.7 | 25.7-31.7 | ||
| Present | 147 | 20.7 | 17.7-23.7 | 1.4 (1.1-1.8) | |
| Lung metastasis | 0.598 | ||||
| Absent | 317 | 24.4 | 21.8-28.0 | ||
| Present | 91 | 26.8 | 22.5-31.0 | 1.1 (0.8-1.5) | |
| Distant lymph node metastasis | 0.063 | ||||
| Absent | 346 | 26.8 | 23.4-30.1 | ||
| Present | 62 | 22.7 | 21.3-24.1 | 1.4 (1.0-2.0) | |
| No. of metastatic organs | 0.001 | ||||
| Single | 286 | 28.0 | 24.0-32.1 | ||
| Multiple | 122 | 20.4 | 16.5-24.3 | 1.6 (1.2-2.1) | |
| No. of metastatic lesions | 0.005 | ||||
| Single | 70 | 35.3 | 23.6-47.0 | ||
| Multiple | 338 | 23.3 | 20.2-26.5 | 1.7 (1.2-2.4) | |
| Secondary metastasis | 0.966 | ||||
| No | 357 | 24.4 | 21.4-27.4 | ||
| Yes | 51 | 26.9 | 22.3-31.5 | 1.0 (0.7-1.5) | |
| Anticancer treatment | <0.001 | ||||
| No | 25 | 11.4 | 10.7-12.0 | ||
| Yes | 383 | 26.9 | 23.8-30.0 | 0.4 (0.2-0.6) | |
| Systemic chemotherapy | <0.001 | ||||
| No | 63 | 15.0 | 9.8-20.2 | ||
| Yes | 345 | 26.9 | 23.4-30.4 | 0.5 (0.4-0.7) | |
| Locoregional radiotherapy | <0.001 | ||||
| No | 194 | 17.7 | 15.5-19.9 | ||
| Yes | 214 | 34.0 | 26.8-41.2 | 0.4 (0.3-0.5) | |
| Local treatment of metastatic disease | 0.017 | ||||
| No | 316 | 23.0 | 19.8-26.2 | ||
| Yes | 92 | 33.3 | 28.8-37.7 | 0.7 (0.5-0.9) | |
| CR | 0.001 | ||||
| No | 375 | 23.1 | 19.9-26.3 | ||
| Yes | 33 | 79.0 | 28.6-129.4 | 0.4 (0.2-0.7) | |
KPS, Karnofsky Performance Scale; CR, complete response; CI, confidence interval; HR, hazard ratio.